AVXL — what changed in the latest 10-Q
A section-by-section comparison of AVXL's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-28 vs the prior 10-Q · 2026-08-28
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +24 | −26 | ~21 | 83 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | +5 | −2 | ~2 | 1 |
| Legal proceedings | Text added/removed | 0 | 0 | ~4 | 4 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-28
Total operating expenses for the three months ended June 30, 2026 were $(6.7) million, compared to $14.5 million for the comparable three months ended June 30, 2025. The primary reason for the decrease in operating expenses is due to the reversal of $15.5 million in stock-based compensation expense …
General and administrative expenses were $(2.0) million for the three months ended June 30, 2026 as compared to $4.5 million for the three months ended June 30, 2025. The decrease was primarily related to the reversal of $7.5 million in stock-based compensation expense during the period. Of the tota…
Our research and development expenses for the three months ended June 30, 2026 were $(4.7) million, as compared to $10.0 million for the three months ended June 30, 2025. The decrease was primarily related to the reversal of $9.9 million in stock-based compensation expense during the period. Of the …
The following table summarizes our research and development expenses for the three months ended June 30, 2026 and 2025 (in thousands):
During the three months ended June 30, 2026 and 2025, external service provider costs by indication and product candidate were as follows (in thousands):
Text removed vs the prior filing · source: 10-Q · 2026-08-28
Comparison of the three months ended March 31, 2026 and 2025
Total operating expenses for the three months ended March 31, 2026 were $6.5 million, compared to $12.5 million for the comparable three months ended March 31, 2025. The primary reason for the decrease in operating expenses is due to the decrease in research and development expenses, which is more f…
General and administrative expenses were $2.3 million for the three months ended March 31, 2026 as compared to $2.6 million for the same quarter of fiscal 2025. The decrease was primarily related to a decrease in legal and professional fees of approximately $0.4 million.
Our research and development expenses for the three months ended March 31, 2026 were $4.2 million as compared to $9.9 million for the three months ended March 31, 2025.
The following table summarizes our research and development expenses for the three months ended March 31, 2026 and 2025 (in thousands):
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-28
As previously disclosed in a Current Report on Form 8-K, filed with the SEC on May 6, 2026, on April 30, 2026, the Special Committee terminated the employment of our former CEO for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between us and our former CEO, as amended and…
During the quarter ended June 30, 2026, building on the leadership change initiated by the Special Committee, we began implementing certain of the remediations and enhancements described in the 2025 Form 10-K/A filed with the SEC on August 28, 2026 to our disclosure and information-communication pro…
·We established a formal Disclosure Committee with defined responsibilities for reviewing significant information relevant to our SEC disclosures; and
·We implemented additional procedures to reconcile significant regulatory, clinical and non-financial source documents to matters contained in our SEC disclosures;
Except for the measures described above, there were no changes in our internal control over financial reporting during the quarter ended June 30, 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We regularly evaluate our con…
Text removed vs the prior filing · source: 10-Q · 2026-08-28
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
The material weakness described in the 2025 Form 10-K/A was identified subsequent to the end of the quarter, and therefore no remediation activities had been designed or implemented as of March 31, 2026. Following the identification of the material weakness, management began developing a remediation…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice